---
title: Olezarsen for Hypertriglyceridemia in Patients at High Cardiovascular Risk
date: '2024-04-08'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/38587249/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1LIK-026Y9bjRE4xDQ231BSa89BnY4O2Rfi-9WXQd8C31C6cqE&fc=20211015124055&ff=20240409180652&v=2.18.0.post9+e462414
source: N Engl J Med
description: 'CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia
  at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides,
  apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified.
  (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, ...'
disable_comments: true
---
CONCLUSIONS: In patients with predominantly moderate hypertriglyceridemia at elevated cardiovascular risk, olezarsen significantly reduced levels of triglycerides, apolipoprotein B, and non-HDL cholesterol, with no major safety concerns identified. (Funded by Ionis Pharmaceuticals; Bridge-TIMI 73a ClinicalTrials.gov number, ...